Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017606 | 0.77 | MAPK14 (0.48) | MAPK14 | |
| SCHEMBL4017462 | 0.77 | MAPK14 (0.40) | MAPK14MAPK11 | |
| SCHEMBL5097303 | 0.74 | MAPK14 (0.48) | MAPK14MAPK11 | |
| SCHEMBL3967133 | 0.71 | MAPK14 (0.56) | MAPK14MAPK11BRD4 | |
| SCHEMBL13764813 | 0.71 | MAPK14 (0.46) | MAPK14MAPK11 | |
| SCHEMBL4013145 | 0.71 | MAPK14 (0.46) | MAPK14MAPK11 | |
| SCHEMBL3966006 | 0.71 | KDM4E (0.42) | MAPK14 | |
| SCHEMBL5107297 | 0.70 | MAPK14 (0.43) | MAPK14MAPK11 | |
| SCHEMBL3967824 | 0.70 | MAPK14 (0.59) | MAPK14MAPK11BRD4 | |
| SCHEMBL3971789 | 0.70 | MAPK14 (0.56) | MAPK14MAPK11BRD4SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563799-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563799-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563799-B2 | Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070049598-A1 | p38 Map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049598-A1 | p38 Map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049598-A1 | p38 Map kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049598-A1 | p38 Map kinase inhibitors and methods for using the same | MAPK1, MAPK3, MAP3K1 | MAPK14 36/4885MAPK11 31/4885BRD4 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.